CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: By identifying innate CD8 T-cells in human peripheral blood as Eomes+ panKIR/NKG2A+ cells27,28, we found a significant increase of innate CD8 T-cell frequency in CML patients after 3 months of dasatinib treatment, as compared to values at diagnosis (Fig. 5A).